StockNews.com Initiates Coverage on TRACON Pharmaceuticals (NASDAQ:TCON)

Stock analysts at StockNews.com began coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON) in a research report issued to clients and investors on Monday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reissued a “neutral” rating on shares of TRACON Pharmaceuticals in a report on Monday, July 1st.

TRACON Pharmaceuticals Price Performance

TCON opened at $0.08 on Monday. The firm has a fifty day moving average price of $0.10 and a 200 day moving average price of $0.76. TRACON Pharmaceuticals has a 1 year low of $0.00 and a 1 year high of $14.75. The stock has a market cap of $273,142.00, a P/E ratio of 0.12 and a beta of 1.36.

TRACON Pharmaceuticals (NASDAQ:TCON) last issued its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.94) earnings per share for the quarter. The business had revenue of $0.06 million for the quarter.

TRACON Pharmaceuticals Company Profile

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.